Galen Vitale
Biology & Medicine · Science
When an Alzheimer’s blood test lands in the middle
Columns
- When an Alzheimer’s blood test lands in the middle
- The patient’s question after a stent is reopened
- The work behind app-supported pregnancy counselling
- The limits of rescue in an Angelman model
- Information useful before surgery
- A lymphoma response comes with a treatment burden
- The boundary between heat-pain relief and protection
- The time invested in easing pain
- LIFT: The care required to raise heart-treatment doses
- What extra effort buys for a liver-fat goal
- The changing weight of Alzheimer’s risk across populations
- The distance from an H1N1 genome to patient protection
- What does a grip test capture in long COVID?
- The care pathway opened by newborn genomic information
- The goal of degrading MDM2 in myelofibrosis
- Dasatinib: four responses do not yet define who should receive it
- A particle stays in the tumour; the dose question reaches toward patients
- How much do Blastocystis subtypes explain bowel pain?
- The risk blood tests describe in gastric cancer
- RAD51D map narrows uncertain genetic results
- Separate traces of aging and Alzheimer's in brain connectivity
- A new route to fetal haemoglobin remains far from patients
- The early story told by a protein in the gut
- Lithium’s WDFY3 result is in cells; families await human evidence
- A 15-minute blood-pressure gap in the emergency department
- The 10-15 per cent GLP-1 drugs barely move
- The Sahel is the denominator for 239,000 extra heat deaths
- Personalized phage therapy has a roadmap before it has strong evidence
- Microbiome timing in type 1 diabetes risk
- Bangladesh measles counts make the cost of vaccination gaps visible again